Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Elisa Fernández-Fernández, Emma Brugarolas, Irene Monjo-Henry, Marta Novella-Navarro, Alejandro Balsa, Eugenio De Miguel
OBJECTIVES: To investigate whether hypoechoic wall thickness is influenced by the systole or diastole moment in the cardiac cycle and if this can influence ultrasound (US) assessments of giant cell arteritis (GCA). METHODS: US videos of 100 consecutive patients (50 with GCA, 50 without) performed between January 2021 and June 2023 were reviewed. Intima-media thickness (IMT) of temporal (including common trunk, frontal and parietal branches), axillary and subclavian arteries were measured at two different time points, at systolic peak (SP) and at the end-diastole (ED)...
May 17, 2024: Rheumatology
#2
JOURNAL ARTICLE
Maria I Zervou, George N Goulielmos
No abstract text is available yet for this article.
May 17, 2024: Rheumatology
#3
JOURNAL ARTICLE
Konstantinos D Vassilakis, Charalampos Papagoras, Nikolaos Fytanidis, Sousana Gazi, Evangelia Mole, Michael Krikelis, Paraskevi V Voulgari, Evripidis Kaltsonoudis, Nikolaos Koletsos, Dimitrios Boumpas, Pelagia Katsimpri, Dimitrios Katsifis-Nezis, Theodoros Dimitroulas, Nikolaos Kougkas, Maria Boutel, Petros P Sfikakis, Maria G Tektonidou, Chrysoula Gialouri, Dimitrios Bogdanos, Theodora Simopoulou, Christos Koutsianas, Evgenia Mavrea, Gkikas Katsifis, Konstantinos Kottas, Maria Konsta, Matthoula Tziafalia, Evangelia Kataxaki, Eleni Kalavri, Kalliopi Klavdianou, Eleftheria P Grika, Charalampos Sfontouris, Dimitrios Daoussis, George Iliopoulos, Ilias Bournazos, Dimitrios Karokis, Konstantinos Georganas, Dimos Patrikos, Dimitrios Vassilopoulos, George E Fragoulis
OBJECTIVE: To present the characteristics of patients with potential difficult-to-treat (D2T) psoriatic arthritis (PsA). METHODS: We used data from the Greek multicentre registry of PsA patients. D2T-PsA was defined as follows: patients with at least 6-months disease duration, who have failed to at least 1 csDMARD and at least 2 bDMARDs/tsDMARDs with a different mechanism of action and have either at least moderate disease activity (MODA) defined as DAPSA > 14, and/or are not at minimal disease activity (MDA)...
May 17, 2024: Rheumatology
#4
JOURNAL ARTICLE
Simon M Petzinna, Lara C Burg, Claus-Juergen Bauer, Pantelis Karakostas, Jan H Terheyden, Charlotte Behning, Frank G Holz, Peter Brossart, Robert P Finger, Valentin S Schäfer
OBJECTIVES: The objective of this study was to prospectively evaluate the diagnostic efficacy of transorbital ultrasound (TOS) in patients newly diagnosed with giant cell arteritis (GCA), presenting with visual symptoms. METHODS: Patients with newly diagnosed, untreated GCA were examined using TOS, assessing central retinal artery flow velocity [peak systolic velocity (PSV), end-diastolic velocity (EDV), resistance index (RI)], and optic nerve diameter (OND). Vascular ultrasound was conducted to evaluate the superficial temporal arteries, their branches, facial, axillary, carotid, and vertebral arteries...
May 17, 2024: Rheumatology
#5
JOURNAL ARTICLE
Daniel S Knight, Ruta Virsinskaite, Nina Karia, Alice R Cole, Rory H Maclean, James T Brown, Rishi K Patel, Yousuf Razvi, Lucia Venneri, Tushar Kotecha, Ana Martinez-Naharro, Peter Kellman, Ann M Scott-Russell, Benjamin E Schreiber, Voon H Ong, Christopher P Denton, Marianna Fontana, J Gerry Coghlan, Vivek Muthurangu
OBJECTIVES: Measures of right heart size and function are prognostic in systemic sclerosis-associated pulmonary hypertension (SSc-PH), but the importance of myocardial tissue characterisation remains unclear. We aimed to investigate the predictive potential and interaction of cardiovascular magnetic resonance (CMR) myocardial tissue characterisation and right heart size and function in SSc-PH. METHODS: A retrospective, single-centre, observational study of 148 SSc-PH patients confirmed by right heart catheterization who underwent clinically-indicated CMR including native myocardial T1 and T2 mapping from 2016 to 2023 was performed...
May 17, 2024: Rheumatology
#6
JOURNAL ARTICLE
Eduardo Martín-Nares, Griselda Romero-Sánchez, Edwin Ulises Cortez-Domínguez, Lilian Guadalupe Cano-Cruz, Andrea Hinojosa-Azaola
OBJECTIVES: We aimed to characterize the clinical and radiological features, and outcomes, of a large cohort of hypertrophic pachymeningitis (HP) patients from a single center. METHODS: We conducted a retrospective study at a tertiary referral center, encompassing patients diagnosed with HP between 2003 and 2022. The diagnosis of HP relied on the identification of thickening of the dura mater via magnetic resonance imaging (MRI) of the brain or spine. RESULTS: We included 74 patients with a mean age of 43...
May 17, 2024: Rheumatology
#7
JOURNAL ARTICLE
Lien Moreel, Albrecht Betrains, Ellen De Langhe, Steven Vanderschueren, Daniel Blockmans
No abstract text is available yet for this article.
May 17, 2024: Rheumatology
#8
JOURNAL ARTICLE
Laure Gossec, Ana-Maria Orbai, Maarten de Wit, Laura C Coates, Alexis Ogdie, Barbara Ink, Jason Coarse, Jérémy Lambert, Vanessa Taieb, Dafna D Gladman
OBJECTIVES: To evaluate 1-year bimekizumab efficacy in psoriatic arthritis (PsA) from the patient perspective using the 12-item PsA Impact of Disease (PsAID-12) questionnaire. METHODS: BE OPTIMAL (NCT03895203; biologic disease-modifying antirheumatic drug [bDMARD]-naïve), BE COMPLETE (NCT03896581; inadequate response/intolerance to tumour necrosis factor inhibitors [TNFi-IR]) and BE VITAL (NCT04009499; open-label extension) assessed bimekizumab 160 mg every 4 weeks in patients with PsA...
May 16, 2024: Rheumatology
#9
JOURNAL ARTICLE
Samuel García
No abstract text is available yet for this article.
May 16, 2024: Rheumatology
#10
JOURNAL ARTICLE
Josephine Therkildsen, Rasmus Klose-Jensen, Mathias Hänel, Bente L Langdahl, Jesper Thygesen, Jesper S Thomsen, Sarah L Manske, Kresten K Keller, Ellen-Margrethe Hauge
OBJECTIVES: To investigate the diagnostic accuracy of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess erosive progression during one year compared to conventional radiography (CR) in rheumatoid arthritis (RA). METHODS: This prospective study included 359 patients with RA (disease duration ≥ 5 years) between March 2018 and October 2020. HR-pQCT and CR were obtained at inclusion and after one year. Erosive assessment was performed at two metacarpophalangeal joints of the dominant hand using HR-pQCT and progression was defined as an increase in erosion number ≥ 1 or an increase in erosive volume > least significant change...
May 15, 2024: Rheumatology
#11
JOURNAL ARTICLE
Lucy Zhao, James Galloway, Jo Ledingham, Sarah Gallagher, Gerasimina Garnavos, Paul Amlani-Hatcher, Nicky Wilson, Lewis Carpenter, Kirsty Bannister, Sam Norton
OBJECTIVES: People with inflammatory arthritis (IA) experience worsened mental wellbeing alongside disease progression. Using the National Early Inflammatory Arthritis Audit (NEIAA), we assessed trends in psychological distress during 12-months following IA diagnosis, mapping these against clinical outcomes to identify associations. METHODS: This is a prospective study of people recruited to NEIAA receiving an IA diagnosis and completing the baseline patient survey...
May 15, 2024: Rheumatology
#12
JOURNAL ARTICLE
Zixing Tian, Lianne Kearsley-Fleet, James Galloway, Kath Watson, Mark Lunt, Kimme L Hyrich
OBJECTIVE: Janus kinase inhibitors (JAKi) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) effectively treat rheumatoid arthritis (RA). However, due to safety concerns, the European Medicines Agency (EMA) published risk minimisation measures limiting JAKi prescription to certain at-risk patients unless no suitable alternative is available. This analysis included patients who had started their first-ever JAKi before EMA measures were published in a large national cohort study to investigate the potential impact of these measures on JAKi prescribing and utilisation in UK...
May 15, 2024: Rheumatology
#13
JOURNAL ARTICLE
Giacomo De Luca, Enrico De Lorenzis, Corrado Campochiaro, Fabio Cacciapaglia, Nicoletta Del Papa, Elisabetta Zanatta, Paolo Airò, Maria Grazia Lazzaroni, Dilia Giuggioli, Maria De Santis, Gabriella Alonzi, Stefano Stano, Marco Binda, Beatrice Moccaldi, Antonio Tonutti, Silvia Cavalli, Veronica Batani, Gerlando Natalello, Florenzo Iannone, Maria Antonietta D'Agostino, Lorenzo Dagna, Marco Matucci-Cerinic, Silvia Laura Bosello
OBJECTIVES: to report real-life data on rituximab retention-rate as indicator of safety and efficacy in a multicentric national cohort of systemic sclerosis patients. METHODS: SSc patients treated with rituximab and followed for at least 36 months were included, clinically characterized, and longitudinally monitored. A competing risk analysis with sub-Hazard Ratio(sHR) definition was performed to explore the clinical variables linked to specific cause of rituximab discontinuation...
May 15, 2024: Rheumatology
#14
JOURNAL ARTICLE
Spyridon Katechis, Dionysis Nikolopoulos, Sofia Flouda, Christina Adamichou, Katerina Chavatza, Noemin Kapsala, Pelagia Katsimbri, George Bertsias, Dimitrios T Boumpas, Antonis Fanouriakis
OBJECTIVES: To discern predictive factors for incident kidney involvement in patients with systemic lupus erythematosus (SLE). METHODS: Patients with SLE from the 'Attikon' Lupus cohort were monitored for lupus nephritis (LN), defined by kidney histology and/or classification criteria. Demographic and clinical characteristics at baseline were compared against patients who did not develop LN. LN-free survival curves were generated by Kaplan-Meier. A multivariate Cox proportional hazards model was used to identify independent predictors of LN...
May 15, 2024: Rheumatology
#15
JOURNAL ARTICLE
Shiri Keret, Boris Chutko, Idit Dobrecky-Mery, Arik Wolak, Emilia Hardak, Gleb Slobodin, Aniela Shouval, Henig Israel, Tsila Zuckerman, Dana Yehudai-Ofir, Dominique Farge, Doron Rimar
No abstract text is available yet for this article.
May 13, 2024: Rheumatology
#16
JOURNAL ARTICLE
Iñigo Rua-Figueroa, I Altabás-González, C Mouriño, K Roberts, A Hernández-Martín, I Casafont-Solé, J Font-Urgelles, J A Román-Ivorra, M de la Rubia Navarro, M Galindo-Izquierdo, T C Salman-Monte, J Narváez, P Vidal-Montal, M J García-Villanueva, S Garrote-Corral, M A Blazquez-Canamero, Carlos Marras Fernandez-Cid, M Piqueras-García, J Martínez-Barrio, M Sánchez-Lucas, J Cortés-Hernández, E Penzo, J Calvo, J R de Dios, B Alvarez-Rodríguez, M Vasques-Rocha, E Tomero, R Menor-Almagro, M Gandía, J A Gómez-Puerta, B Frade-Sosa, C Ramos-Giráldez, C Trapero-Pérez, E Diez, C Moriano, A Muñoz-Jiménez, J M Pego-Reigosa
OBJECTIVES: The aims of this study were to investigate the prevalence of dose reduction in patients with SLE treated with belimumab (BEL) in Spain, analyze treatment modalities, and determine impact on control of disease activity. METHODS: Retrospective longitudinal and multicentre study of SLE patients treated with BEL. Data on disease activity, treatments and outcomes were recorded before and after reduction (6-12 months), and they were compared. RESULTS: A total of 324 patients were included...
May 13, 2024: Rheumatology
#17
JOURNAL ARTICLE
Kornelis S M van der Geest, Maria Sandovici, A Rutgers, Elisabeth Brouwer
No abstract text is available yet for this article.
May 13, 2024: Rheumatology
#18
JOURNAL ARTICLE
Kanon Jatuworapruk, Patnarin Pongkulkiat
No abstract text is available yet for this article.
May 13, 2024: Rheumatology
#19
JOURNAL ARTICLE
Rahaymin Chowdhury, Nawaz Z Safdar, Deborah Ab Ellames, Richard J Wakefield
No abstract text is available yet for this article.
May 11, 2024: Rheumatology
#20
JOURNAL ARTICLE
Eun Ha Kang, Anna Shin, Chang Soo Park, Eun Bong Lee, Yun Jong Lee, Gary Curhan, Hyon K Choi
OBJECTIVES: To compare the risk of urolithiasis in gout patients initiating allopurinol, a xanthine oxidase inhibitor, vs benzbromarone, a uricosuric. METHODS: Using the 2011-2020 Korea National Health Insurance Service database, we conducted a cohort study on gout patients initiating allopurinol vs benzbromarone as the 1st-line urate-lowering treatment (ULT). The primary outcome was a new onset urinary stone. The secondary outcome was a stone requiring intervention...
May 11, 2024: Rheumatology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
